A gene expression profile for detection of sufficient tumour cells in breast tumour tissue: microarray diagnosis eligibility.
BACKGROUND
Microarray diagnostics of tumour samples is based on measurement of prognostic and/or predictive gene expression profiles. Typically, diagnostic profiles have been developed using bulk tumour samples with a sufficient amount of tumour cells (usually >50%). Consequentially, a diagnostic results depends on the minimal percentage of tumour cells within a sample. Currently, tumour cell percentage is assessed by conventional histopathological review. However, even for experienced pathologists, such scoring remains subjective and time consuming and can lead to ambiguous results.


METHODS
In this study we investigated whether we could use transcriptional activity of a specific set of genes instead of histopathological review to identify samples with sufficient tumour cell content. Genome-wide gene expression measurements were used to develop a transcriptional gene profile that could accurately assess a sample's tumour cell percentage.


RESULTS
Supervised analysis across 165 breast tumour samples resulted in the identification of a set of 13 genes which expression correlated with presence of tumour cells. The developed gene profile showed a high performance (AUC 0.92) for identification of samples that are suitable for microarray diagnostics. Validation on 238 additional breast tumour samples indicated a robust performance for correct classification with an overall accuracy of 91 percent and a kappa score of 0.63 (95%CI 0.47-0.73).


CONCLUSIONS
The developed 13-gene profile provides an objective tool for assessment whether a breast cancer sample contains sufficient tumour cells for microarray diagnostics. It will improve the efficiency and throughput for diagnostic gene expression profiling as it no longer requires histopathological analysis for initial tumour percentage scoring. Such profile will also be very use useful for assessment of tumour cell percentage in biopsies where conventional histopathology is difficult, such as fine needle aspirates.
Roepman
Paul
P
Agendia BV, Science Park 406, 1098XH, Amsterdam, the Netherlands. paul.roepman@agendia.com
Schuurman
Arenda
A
Delahaye
Leonie J M J
LJ
Witteveen
Anke T
AT
Floore
Arno N
AN
Glas
Annuska M
AM
Nat Rev Cancer. 2004 Nov;4(11):839-49
15516957
Nature. 2002 Jan 31;415(6871):530-6
11823860
Ann Thorac Surg. 2007 Dec;84(6):1825-9
18036892
Am J Surg Pathol. 2003 Jun;27(6):805-10
12766585
BMC Genomics. 2006 Oct 30;7:278
17074082
Clin Cancer Res. 2007 May 15;13(10):2831-5
17504980
Cancer Res. 2006 Feb 15;66(4):2361-6
16489042
Nat Rev Cancer. 2006 May;6(5):392-401
16572188
Histopathology. 2006 Jun;48(7):787-94
16722926
Nature. 2006 May 25;441(7092):444-50
16724056